New York State Teachers Retirement System Reduces Holdings in AbbVie Inc. $ABBV

New York State Teachers Retirement System cut its stake in AbbVie Inc. (NYSE:ABBV) by 2.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,480,217 shares of the company’s stock after selling 44,052 shares during the period. AbbVie comprises approximately 0.7% of New York State Teachers Retirement System’s portfolio, making the stock its 20th largest position. New York State Teachers Retirement System’s holdings in AbbVie were worth $342,729,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC increased its position in AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. lifted its stake in AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new position in shares of AbbVie during the second quarter worth approximately $581,817,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 1.8%

Shares of NYSE:ABBV opened at $220.06 on Friday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a 50-day moving average price of $226.59 and a 200 day moving average price of $215.32. The company has a market cap of $388.93 billion, a P/E ratio of 166.71, a PEG ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Citigroup dropped their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.